COVID-19 promotes life-saving policy change for opioid addiction

Facing the US pandemic COVID-19. USA, The US Administration of Mental Health and Substance Abuse Services. USA (SAMHSA) has announced new policy changes regarding home treatment of opioid use disorder (OUD). Last week, the agency issued a directive to allow some patients in opioid treatment (OTP) programs to take their medications home, announcing that states may request "general exceptions" for all stable patients in an OTP to receive a 28-day supply of home-dose medications such as methadone and buprenorphine, for the treatment of opioid use disorder (OUD). The agency also said states can now request up to 14 days of take-home medications for patients who are less stable but who, in OTP doctors' opinion, can safely handle this level of take-home medications. "SAMHSA recognizes the evolving problems surrounding COVID-19 and the emerging needs that OTPs continue to face," the agency writes.

> Read the article

Source: NewsDio is a website intended to deliver news related to Business, Tech, Finance, and Sports networks, March 21, 2020
Source: Substance Abuse and Mental Health Services Administration https://www.samhsa.gov/coronavirus

COVID-19: Potential Implications for Individuals with Substance Use Disorders

As people across the U.S. and the rest of the world contend with coronavirus disease 2019 (COVID-19), the research community should be alert to the possibility that it could hit some populations with substance use disorders (SUDs) particularly hard. People with opioid use disorder (OUD) and methamphetamine use disorder may also be vulnerable due to those drugs’ effects on respiratory and pulmonary health. 

> Read the article.

Source: NIDA. (2020, March 12). COVID-19: Potential Implications for Individuals with Substance Use Disorders. Retrieved from https://www.drugabuse.gov/about-nida/noras-blog/2020/03/covid-19-potential-implications-individuals-substance-use-disorders on 2020, March 20

Opioid Withdrawal Raises Health Risks for Injection Drug Users: Study

Health Day, March 23, 2020
Having opioid withdrawal symptoms increases the odds that injection drug users will share needles or have a non-fatal overdose, new research suggests. For the study, the researchers questioned more than 800 injection drug users in San Francisco and Los Angeles. "Withdrawal is one of the main chronic health challenges for this population, and we need to be intervening on it," said lead author Ricky Bluthenthal. He's associate dean for social justice at the University of Southern California's Keck School of Medicine, in Los Angeles. An average 130 people a day die in the United States from an opioid overdose, according to the U.S. Centers for Disease Control and Prevention. Needle sharing increases a person's risk of infections such as HIV and hepatitis, as well as other serious health problems, the CDC says.

> Read the article

AMA's "Opioid Task Force 2019 Progress Report”

The AMA Opioid Task Force urges physicians and other health care professions to continue taking action to help reverse the nation’s opioid epidemic, and the Task Force also calls on policymakers to take specific steps to remove barriers to evidence-based care for patients with pain and those with a substance use disorder. The 2019 progress report highlights physician action and the immediate need for policymakers to focus on removing barriers to evidence-based treatment.

  • America’s physicians are using state prescription drug monitoring programs more than ever.
  • The AMA Opioid Task Force encourages all physicians to enhance their education.
  • The AMA Opioid Task Force urges expanded access to Naloxone.

> Download the Report



©2020 Ventura County Behavioral Health • Hanstad Consulting • Website: Idea Engineering